Patents by Inventor David LIBERG

David LIBERG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190394706
    Abstract: In certain embodiments, a method of operating a wireless communication device comprises receiving a narrowband secondary synchronization signal (NSSS) in a discovery reference signal (DRS), identifying a transformation applied to the NSSS, and determining a DRS periodicity based on the identified transformation.
    Type: Application
    Filed: June 22, 2018
    Publication date: December 26, 2019
    Inventors: Mai-Anh Phan, David Sugirtharaj, Emma Wittenmark, Oskar Drugge, Olof Liberg
  • Patent number: 10314836
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: June 11, 2019
    Assignee: Active Biotech AB
    Inventors: David Liberg, Anders Olsson, Dmitry Gabrilovich, Yuliya Nefedova
  • Patent number: 10125125
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 13, 2018
    Assignee: Active Biotech AB
    Inventors: Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
  • Publication number: 20180228794
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Application
    Filed: April 6, 2018
    Publication date: August 16, 2018
    Inventors: David LIBERG, Anders OLSSON, Dmitry GABRILOVICH, Yuliya NEFEDOVA
  • Publication number: 20180155330
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 7, 2018
    Inventors: Ingela FRITZSON, David LIBERG, Stephen EAST, Colin MACKINNON, Natacha PREVOST
  • Patent number: 9956212
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: May 1, 2018
    Assignee: Active Biotech AB
    Inventors: David Liberg, Anders Olsson, Dmitry Gabrilovich, Yuliya Nefedova
  • Patent number: 9873687
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: January 23, 2018
    Assignee: Active Biotech AB
    Inventors: Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
  • Publication number: 20170273967
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of multiple myeloma.
    Type: Application
    Filed: September 18, 2015
    Publication date: September 28, 2017
    Inventors: David LIBERG, Anders OLSSON, Dmitry GABRILOVICH, Yuliya NEFEDOVA
  • Patent number: 9771372
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 26, 2017
    Assignee: Active Biotech AB
    Inventors: Ulf Wellmar, David Liberg, Maria Ekblad, Marie Bainbridge, Stephen East, Jonathan Hargrave, Natacha Prevost
  • Publication number: 20170204098
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 22, 2015
    Publication date: July 20, 2017
    Inventors: Ulf WELLMAR, David LIBERG, Maria EKBLAD, Marie BAINBRIDGE, Stephen EAST, Jonathan HARGRAVE, Natacha PREVOST
  • Publication number: 20160115158
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 14, 2014
    Publication date: April 28, 2016
    Inventors: Ingela FRITZSON, David LIBERG, Stephen EAST, Colin MACKINNON, Natacha PREVOST